Market Overview

PAREXEL's Xavier Flinois Named to 2018 PharmaVOICE 100

Share:

PAREXEL International Corporation, the world's leading innovator of
biopharmaceutical services, today announced that Xavier Flinois,
President of PAREXEL Informatics, has been named to PharmaVOICE
magazine's list of the 100 most inspiring people in the life sciences
industry. The honor, published in the July/August 2018 issue of PharmaVOICE,
recognizes Mr. Flinois' contributions to the industry through leadership
and innovation.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180801005514/en/

Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE magazine's list of t ...

Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE magazine's list of the 100 most inspiring people in the life sciences industry. (Photo: Business Wire)

Mr. Flinois has more than 25 years of experience in the technology and
healthcare IT sectors. Since 2013, he has led PAREXEL in developing
industry-leading technological innovations and solutions to enhance drug
development aimed at making the process faster, more accurate, more
productive and easier to track. Most recently, Mr. Flinois drove
PAREXEL's technology development alliance with Microsoft. He also led
the launch of Perceptive® Cloud, a platform delivering
PAREXEL solutions on an enhanced, global, secure cloud infrastructure.
In addition, Mr. Flinois spearheaded the development and launch of
PAREXEL's Patient Sensor Solution and drove the Company's collaboration
with Sanofi, both with the goal of advancing the use of wearable devices
to transform data collection in clinical trials.

"Xavier is a strong leader for PAREXEL who consistently demonstrates
leadership and a drive for innovation," said Jamie Macdonald, Chief
Executive Officer, PAREXEL. "Our industry has undergone many changes
over the last several years – from the surge of availability of data to
the digitization of clinical development and availability of new
technologies. Xavier has led PAREXEL in our efforts to leverage these
advances to improve drug development and ultimately help our clients
more efficiently and effectively deliver important new therapies to
patients sooner. We are pleased to see that PharmaVOICE has
recognized Xavier as one of the most inspiring people in life sciences,
as it is a testament to his innovation, leadership and contribution to
the industry."

The annual PharmaVOICE 100 list honors a select group of leaders
in the life sciences who positively impact their colleagues, peers,
organizations, and the industry at large. These individuals are
passionate, forward-thinkers who actively work to address industry
challenges and trends. To read the 2018 PharmaVOICE profiles,
visit www.pharmavoice.com

About PAREXEL International

PAREXEL International Corporation is the world's leading innovator of
biopharmaceutical services. We simplify our clients' journey of
transforming scientific discoveries into new medical treatments for
patients with high-quality Phase I-IV clinical research, regulatory,
consulting and market access services. PAREXEL develops breakthrough
innovations and solutions by leveraging its comprehensive therapeutic,
technical and functional expertise, in more than 100 countries around
the world. For more information visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation.
All other trademarks are the property of their respective owners.

View Comments and Join the Discussion!